Eosinophils in COPD: just another biomarker?

M Bafadhel, ID Pavord, REK Russell - The Lancet Respiratory …, 2017 - thelancet.com
Eosinophils are innate immune cells that, under certain conditions, can be recruited to the
lungs, where they have an incompletely understood role in health and disease. Eosinophils …

A review of national guidelines for management of COPD in Europe

M Miravitlles, C Vogelmeier, N Roche… - European …, 2016 - Eur Respiratory Soc
The quality of care can be improved by the development and implementation of evidence-
based treatment guidelines. Different national guidelines for chronic obstructive pulmonary …

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials

M Bafadhel, S Peterson, MA De Blas… - The Lancet …, 2018 - thelancet.com
Background The peripheral blood eosinophil count might help identify those patients with
chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations …

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis

GJ Rodrigo, D Price, A Anzueto, D Singh… - … journal of chronic …, 2017 - Taylor & Francis
Background Randomized controlled trials (RCTs) indicate that long-acting bronchodilator
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …

[HTML][HTML] Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD

JAM Westerik, EI Metting, JFM van Boven… - Respiratory …, 2017 - Springer
Background COPD often coexists with chronic conditions that may influence disease
prognosis. We investigated associations between chronic (co) morbidities and …

[HTML][HTML] Rational use of inhaled corticosteroids for the treatment of COPD

JK Quint, A Ariel, PJ Barnes - npj Primary Care Respiratory Medicine, 2023 - nature.com
Inhaled corticosteroids (ICS) are the mainstay of treatment for asthma, but their role in
chronic obstructive pulmonary disease (COPD) is debated. Recent randomised controlled …

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® …

KM Beeh, E Derom, J Echave-Sustaeta… - … journal of chronic …, 2016 - Taylor & Francis
Background Tiotropium+ olodaterol has demonstrated improvements beyond lung function
benefits in a large Phase III clinical program as a once-daily maintenance treatment for …

Barriers and enablers of physical activity engagement for patients with COPD in primary care

MC Kosteli, NR Heneghan, C Roskell… - … journal of chronic …, 2017 - Taylor & Francis
Background Given that physical activity (PA) has a positive impact on COPD symptoms and
prognosis, this study examined the factors that both encourage and limit participation in PA …

Greater dyspnea is associated with lower health-related quality of life among European patients with COPD

JB Gruenberger, J Vietri, DL Keininger… - International journal of …, 2017 - Taylor & Francis
Objective Dyspnea is a defining symptom in the classification and treatment of chronic
obstructive pulmonary disease (COPD). However, the degree of variation in burden among …

Comprehensive care programme for patients with chronic obstructive pulmonary disease: a randomised controlled trial

FWS Ko, NK Cheung, TH Rainer, C Lum, I Wong… - Thorax, 2017 - thorax.bmj.com
Background There have been no randomised controlled trials that specifically evaluate the
effect of a comprehensive programme with multidisciplinary input on patients who have just …